ABSTRACT:
A monoclonal antibody called itepekimab targets interleukins and has been demonstrated to lessen tissue damage and airway inflammation. Lung chronic inflammatory disorders rank among the world's major causes of death and substantial morbidity. The majority of these diseases still have few available treatments, despite the enormous strain they place on the world's healthcare system. Although readily accessible and useful for managing symptoms, inhaled corticosteroids and beta-adrenergic agonists have serious and escalating adverse effects that impair long-term patient compliance. . Biologic medications, including monoclonal antibodies and peptide inhibitors, have potential as treatments for long-term lung conditions. While monoclonal antibodies have previously been used as medicines for a variety of ailments, peptide inhibitor-based treatments have also been proposed for a number of diseases, including cancer, infectious disorders, and even Alzheimer's disease. A number of biologic medicines are presently under development to treat pulmonary sarcoidosis, idiopathic pulmonary fibrosis, asthma, and chronic obstructive pulmonary disease. With an emphasis on the results of randomized clinical trials, this article reviews the biologics now used to treat chronic inflammatory pulmonary disorders as well as recent developments in the creation of the most promising of those therapies.
Cite this article:
Faisal Shaikh, Dr. G.J. Khan, Rehan Deshmukh, Aman Shaikh, M Sohil M Shabbir. A Review On Itepekimab: An Investigational Drug.IJRPAS, 2024; 3(6): 125-130.
1. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa G Della, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol [Internet]. 2001;108(2):184–90. Available from: https://www.sciencedirect.com/science/article/pii/S0091674901659451
2. Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288–98.
3. Miyaoka C, Watanabe M, Nakamoto K, Yoshida Y, Hirata A, Aso J, et al. Association of IL-33 in modeling type-2 airway inflammation and pulmonary emphysema in mice. Immunity, Inflamm Dis. 2024 Apr;12(4):e1252.
4. Jo YS, Rhee CK, Yoon HK, Park CK, Lim JU, An TJ, et al. Evaluation of asthma-chronic obstructive pulmonary disease overlap using a mouse model of pulmonary disease. J Inflamm (Lond). 2022 Dec;19(1):25.
5. Plichta J, Kuna P, Panek M. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives. Front Immunol. 2023;14:1207641.
6. Medzhitov R. Origin and physiological roles of inflammation. Nature [Internet]. 2008;454(7203):428–35. Available from: https://doi.org/10.1038/nature07201
7. GBD. Global burden of 369 diseases and injuries in 204 countries and territories, 19902019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England). 2020 Oct;396(10258):1204–22.
8. Upadhyay R, Sanchez-Hidalgo A, Wilusz CJ, Lenaerts AJ, Arab J, Yeh J, et al. Host Directed Therapy for Chronic Tuberculosis via Intrapulmonary Delivery of Aerosolized Peptide Inhibitors Targeting the IL-10-STAT3 Pathway. Sci Rep. 2018 Nov;8(1):16610.
9. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.
10. Schütz D, Ruiz-Blanco YB, Münch J, Kirchhoff F, Sanchez-Garcia E, Müller JA. Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv Drug Deliv Rev. 2020 Dec;167:47–65.
11. Liu M, Li C, Pazgier M, Li C, Mao Y, Lv Y, et al. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A. 2010 Aug;107(32):14321–6.
12. Kumar J, Sim V. D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. Prion. 2014;8(1):119–24.
13. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015 Jan;16(1):45–56.
14. Chiu C-J, Huang M-T. Asthma in the Precision Medicine Era: Biologics and Probiotics. Int J Mol Sci. 2021 Apr;22(9).
15. Matucci A, Vivarelli E, Nencini F, Maggi E, Vultaggio A. Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors. Biomedicines. 2021 Oct;9(10).
16. Kyriakopoulos C, Gogali A, Bartziokas K, Kostikas K. Identification and treatment of T2low asthma in the era of biologics. ERJ open Res. 2021 Apr;7(2).
17. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet (London, England). 2015 Mar;385(9971):899–909.
18. Barnes PJ. Small airway fibrosis in COPD. Int J Biochem Cell Biol. 2019 Nov;116:105598.
19. Zhu J, Kovacs L, Han W, Liu G, Huo Y, Lucas R, et al. Reactive Oxygen SpeciesDependent Calpain Activation Contributes to Airway and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. Antioxid Redox Signal. 2019 Oct;31(12):804–18.
20. Zeng Q, Zeng J. Inhibition of miR-494-3p alleviates oxidative stress-induced cell senescence and inflammation in the primary epithelial cells of COPD patients. Int Immunopharmacol. 2021 Mar;92:107044.
21. Navratilova Z, Kolek V, Petrek M. Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease. Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):177–93.
22. Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what? Clin Respir J. 2012 Oct;6(4):208–14.
23. David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021 Feb;76(2):188–95.
24. King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015 Dec;4(1):68.
25. Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019 Aug;54(2).
26. Barnes PJ. Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold? Semin Respir Crit Care Med. 2015 Aug;36(4):508–22.
27. Cazzola M, Matera MG. Is it time to look beyond bronchodilators and corticosteroids in treating COPD? Vol. 3, Future Drug Discovery. Future Science; 2021. p. FDD61.